Table 1.
Patient characteristics.
| Patient Characteristic | Number (Percentage) |
|---|---|
| Gender | |
| Male | 70 (56%) |
| Female | 55 (44%) |
| Age, years | |
| Median + IQR | 62 (55–68) |
| Range | 19–89 |
| Side of Primary | |
| Left | 82 (66%) |
| Right | 43 (34%) |
| KRAS Mutation | |
| Mutant | 48 (47%) |
| Wild Type | 54 (53%) |
| Missing | 23 |
| BRAF Mutation | |
| Mutant | 10 (10%) |
| Wild Type | 86 (90%) |
| Missing | 29 |
| Carcinoembryonic Antigen CEA | |
| Elevated (range) | 49 (77%) (5.4–28326) |
| Normal | 15 (13%) |
| Missing | 61 |
| Location of Metastases | |
| Liver-Only | 55 (44%) |
| Lung-Only | 9 (7%) |
| Multiple Sites (>1) | 61 (49%) |
| Adjuvant therapy | |
| Yes | 23 (180%) |
| No | 102 (82%) |
| Neoadjuvant therapy | |
| Yes | 27 (22%) |
| No | 98 (78%) |
| Number of Lines Palliative Chemotherapy | |
| 0 | 23 (18%) |
| 1 | 37 (30%) |
| 2 | 17 (14%) |
| 3 | 24 (19%) |
| ≥4 | 24 (19%) |
| Number of Multimodal Procedures | |
| 0 | 51 (40.8%) |
| 1 | 35 (28%) |
| 2 | 17 (13.6%) |
| ≥3 | 22 (17.6%) |